- Home
- CHRS vs CFBK Comparison
CHRS vs CFBK Comparison
Compare CHRS & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CFBK
- Stock Information
- Founded
- CHRS 2010
- CFBK 1892
- Country
- CHRS United States
- CFBK United States
- Employees
- CHRS N/A
- CFBK N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CFBK Major Banks
- Sector
- CHRS Health Care
- CFBK Finance
- Exchange
- CHRS Nasdaq
- CFBK Nasdaq
- Market Cap
- CHRS 84.2M
- CFBK 154.9M
- IPO Year
- CHRS 2014
- CFBK 1998
- Fundamental
- Price
- CHRS $0.90
- CFBK $24.03
- Analyst Decision
- CHRS Buy
- CFBK Buy
- Analyst Count
- CHRS 3
- CFBK 1
- Target Price
- CHRS $4.68
- CFBK $29.00
- AVG Volume (30 Days)
- CHRS 1.3M
- CFBK 42.7K
- Earning Date
- CHRS 08-07-2025
- CFBK 08-05-2025
- Dividend Yield
- CHRS N/A
- CFBK 1.32%
- EPS Growth
- CHRS N/A
- CFBK N/A
- EPS
- CHRS N/A
- CFBK 2.28
- Revenue
- CHRS $272,251,000.00
- CFBK $47,663,000.00
- Revenue This Year
- CHRS N/A
- CFBK $35.39
- Revenue Next Year
- CHRS $99.43
- CFBK $10.11
- P/E Ratio
- CHRS $2.07
- CFBK $10.53
- Revenue Growth
- CHRS 19.87
- CFBK 1.22
- 52 Week Low
- CHRS $0.66
- CFBK $18.72
- 52 Week High
- CHRS $2.43
- CFBK $31.17
- Technical
- Relative Strength Index (RSI)
- CHRS 59.04
- CFBK 56.24
- Support Level
- CHRS $0.73
- CFBK $23.84
- Resistance Level
- CHRS $0.82
- CFBK $24.50
- Average True Range (ATR)
- CHRS 0.04
- CFBK 0.40
- MACD
- CHRS 0.02
- CFBK 0.03
- Stochastic Oscillator
- CHRS 88.02
- CFBK 60.94
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.